Roche Diagnostics is proud to announce that the cobas® pulse system is now Health Canada approved!

Lire la version française

The wait is over!  Roche Diagnostics Canada is pleased to announce the launch of the cobas® pulse system following Health Canada’s approval.  This is the industry’s first professional blood glucose management solution with mobile digital health capabilities to improve patient care.

  • Handheld blood glucose management device designed to meet the specific needs of healthcare professionals in various healthcare settings.

  • The first diagnostic solution at the point of care to serve as a digital platform, connecting developers of digital health software and applications to healthcare professionals.

  • Introduces several advancements aimed at dramatically simplifying workflows for busy nurses, doctors, and other healthcare professionals, improving their ability to deliver patient care at the bedside.

  • Reliable and safe to use in all professional care settings (including intensive care) and with patients of all ages (including neonates).

  • Equips healthcare professionals with a truly novel solution that provides actionable clinical insights and a near-limitless range of digital capabilities for patient care.  

What is the cobas® pulse system?

The cobas® pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities, similar to that of a smartphone. It was designed for professional use in a range of care settings where timely and informed clinical decisions are needed.The cobas® pulse system is Roche’s newest generation of connected professional blood glucose management solutions, building on its legacy with Accu-Chek® Inform II.  It was designed with advanced safety, performance, simplicity, and enhanced digital power at its core to serve as a gateway to the future of digital health – improving workflows and changing healthcare in favour of cost efficiency and better patient care.  It features outstanding performance that meets the criteria of one of the latest guidelines for glucose meters1. It is free from interference and features an easy-to-clean and robust design equipped for 12,000 cycles of cleaning and disinfection. 

The cobas® pulse system’s portability and intuitive Android-based interface make using it as simple as a smartphone. Among several other innovations, the cobas® pulse system features an illuminated glucose strip port for ease of use in poorly lit environments, wireless charging, an embedded camera for multiple uses, and secure RFID badging. Cobas® infinity edge smart equips the cobas® pulse system with Roche-selected digital health applications that enable a truly versatile range of operations for patient and workflow management.

  • Glucose is among the most important biomarkers to assess patient health and to predict, diagnose, and manage metabolic disorders2. In particular, the management of blood glucose in patients is critical to preventing acute and chronic complications that may lead to increased morbidity, mortality and healthcare costs3,5,6,7. 

  • Against the backdrop of a rising epidemic of diabetes3 and other non-communicable diseases, the need to regularly perform this critical intervention adds to an ever-growing list of responsibilities facing stretched healthcare systems and professionals. 

  • Frontline healthcare professionals are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care. This is particularly true when it comes to the management of blood glucose, which remains critical to preventing acute and chronic complications that may lead to increased morbidity, mortality, and healthcare costs.

"The cobas® pulse system represents a significant advancement in near-patient-care testing, offering a powerful tool for healthcare professionals. Its integration of digital health capabilities with robust blood glucose management functionality will streamline workflows and enhance patient care, setting a new standard in the industry."   - Peter Geimer, Director of Marketing & Strategy - Near Patient Care, Roche Diagnostics Canada

For the first time in a point of care device, the cobas® pulse system will act as a digital platform that connects innovative third party applications and software with healthcare professionals -- creating a digital ecosystem designed to improve hospital efficiency and patient care. 

The system comes equipped with Roche-selected third-party digital health applications based on the Android operating system that perform a range of clinically valuable functions – from clinical decision support to the measurement of vital signs and digital biomarkers. The apps are distributed by a digital platform called cobas® infinity edge smart, the newest module of Roche’s software solutions.

The pairing of the cobas® pulse system with cobas® infinity edge smart marks the first integrated solution from Roche Diagnostics to leverage a pioneering business-to-business partnership model that enables external tech companies to access healthcare professionals as customers and put digital health applications at their fingertips. 

When cobas® pulse system and cobas® infinity edge smart are combined, the solution facilitates the ability of labs and hospitals to manage patient-testing devices (Roche and non-Roche) that measure clinical health parameters anytime, anywhere. cobas® infinity edge also enables the deployment of third party applications into point of care devices. 

With this digital ecosystem approach, lab and hospital administrators can also better govern, update and manage use of near-patient testing devices -- even remotely. 

The platform uses industry-standard security technologies and processes to connect to electronic medical record systems (EMRs) as well as enabling remote installations, service, and maintenance of devices outside the lab/hospital premises (e.g., clinics or pharmacies). This solution will bring more diagnostic capabilities – safely and securely -- beyond the lab walls, closer to physicians and nurses at the points where clinical decisions are being made.

With growing investments in digital capabilities, Roche is building on its expertise in science, medicine, and technology to increasingly leverage data analytic tools and novel digital technologies to transform the way healthcare is delivered and managed for each patient. Our data-driven digital solutions empower labs, healthcare providers, and patients to make informed, insights-based decisions across the entire care continuum – reducing costs to society and improving patient health outcomes in the process.

Access the following link to learn more about the cobas® pulse system:

https://www.rochecanada.com/landing-pages/cobas-pulse


References

1 CLSI POCT12-A3 Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities. Clinical and Laboratory Standards Institute, 2013.

2 Krentz AJ et al. (2016). Biomark Med. 10(11):1153-1166.

3 Pasquel FJ et al. (2021). Lancet Diab Endocrinol 9: 174–88.

4 DF DIABETES ATLAS (2019). Ninth edition. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Accessed September 2021.

5 ADA Standards of Medical Care in Diabetes. (2021). Diabetes care 44: Suppl 1.

6 Dhatariya K et al. (2020). NCBI Bookshelf.

7 Hermanides J et al. (2010). Crit Care Med 38(3): 1430-34.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactWorldwideFighting Against Forced LabourlinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsDiagnostics solutionCareersMediaPrivacy policyLegal statementSocial Media PolicyAccessibility

You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.